Cyclo3pss Corp
Change company Symbol lookup
Select an option...
CYPS Cyclo3pss Corp
CXW CoreCivic Inc
STM STMicroelectronics NV
NYT New York Times Co
SOS Sos Ltd
DDOC DERMADOCTOR, INC.
CLOV Clover Health Investments Corp
POL Polished.Com Inc
ENJYQ Legacy EJY Inc
EVV Eaton Vance Limited Duration Income Fund
Go

Company profile

Cyclo3pss Corporation is engaged in designing, manufacturing, assembling, sale and installation of ozone application technologies and processes. The Company's principal technology provides an alternative to address food safety and sanitation concerns, healthcare sanitizing, and laundry disinfection and efficiency. The Company’s products include Ster-O3-Zone, Eco Wash and Eco Pure products. Ster-O3-Zone is a medical sterilizer which includes a series of products developed for the medical and pharmaceutical industries. Eco Wash is a laundry equipment which serves the customers in hotel, nursing home and institutional markets. Eco Pure works in projects applying ozone to the sanitizing of turkey, beef, and pork carcasses, as well as brine used in cured meat products.

Closing Price
$0.00
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.00
Day's Low
0.00
Volume
55,000

Bed Bath & Beyond's turnaround plan leaves 'questions that have really not been answered to any degree'

8:15 am ET September 28, 2022 (MarketWatch)
Print

By Bill Peters

Earnings preview: Struggling retailer expected to provide further clarity on turnaround plan that could lead to 'duration fatigue,' analyst says

When Bed Bath & Beyond Inc. reports fiscal second-quarter earnings on Thursday, analysts will have one big question on their minds: When will turnaround efforts pay off?

The results for the home-goods retailer, which sells items like bedsheets, towels and cookware, will arrive after an epic rise and fall for the "meme stock" amid moves by an activist investor, aggressive cutbacks and the death of an executive that was ruled a suicide. Bed Bath & Beyond's (BBBY) turnaround efforts will be the focus of this report, and analysts already have their doubts about executives' plans coming to fruition anytime soon.

Morningstar analyst Jaime Katz said she would be looking for more specifics on the second half of the company's fiscal year on Thursday, as well as what executives' efforts to right the ship mean longer term for operating margins. For now, she said, the plan lacks "newness" -- returning to selling national brands that don't provide the retailer with pricing power, after walking back plans to sell cheaper, private-label fare that had unfocused messaging, is unlikely to be enough.

"There's this duration fatigue," Katz said in an interview with MarketWatch. "When does it find its footing?"

Bed Bath & Beyond has pruned executives, slashed jobs, product offerings and spending, and announced plans to close dozens of stores. The company last month said it secured $500 million in new financing. It ended its fiscal first quarter with cash and equivalents of around $108 million, down from around $1.1 billion in the year-earlier period.

While those cuts seem like a start to the plan, the full course is still in question, Katz said, and the end appears to be nowhere in sight. Executives will attempt to give more clarity in a conference call Thursday morning following the release of the results.

"Whenever you think you're sort of that the bottom, we haven't really found it yet," Katz said. "Are we there? What does that look like? Those are questions that have really not been answered to any degree."

What to expect

Earnings: Analysts polled by FactSet on average expect Bed Bath& Beyond to lose $1.79 a share on an adjusted basis, compared with a 4 cents a share in earnings a year ago. That would mark the retailer's fourth consecutive per-share loss, according to FactSet.

Contributors to Estimize -- a crowdsourcing platform that gathers estimates from Wall Street analysts as well as buy-side analysts, fund managers, company executives, academics and others -- on average are expecting a bigger loss of $1.94 a share.

Revenue: Bed Bath & Beyond is expected to report sales of $1.447 billion on average, FactSet reports, compared with $1.985 billion in the year-earlier period. Estimize contributors predict $1.431 billion on average.

Stock Price: Bed Bath & Beyond stock finished 4.5% lower on Monday, and is down 56% so far this year. By comparison, the S&P 500 is down 23% in 2022.

Earlier in the year, activist investor Ryan Cohen -- the chairman of fellow meme stock GameStop Inc. (GME) and the founder of online pet-supplies retailer Chewy Inc. (CHWY)-- disclosed a large stake in Bed Bath & Beyond. But Cohen last month unloaded that position, selling off what amounted to 11.8% of the company's shares outstanding. Shares nosedived, not long after meme traders banded together to drive the stock higher.

What to watch for

Katz also noted that Bed Bath & Beyond reports as higher interest rates eat into demand on the housing market, and, potentially, the home furnishings sold at retailers. Analysts say the company, considered a "category killer" in decades past, was late on building its e-commerce infrastructure, and it has faced tougher competition from other big-box retailers and Amazon.com Inc. (AMZN) .

A rushed rollout of cheaper private-label offerings through the pandemic ran up against supply-chain snarls and lukewarm consumer enthusiasm, the Wall Street Journal reported. The pandemic's stay-at-home boom gave way to the return of travel and entertainment and higher prices.

Mark Tritton, the chief executive who oversaw that private-label rollout, departed in June. Chief Financial Officer Gustavo Arnal died early this month after falling from a skyscraper in Manhattan, not long after a lawsuit alleging he and Cohen engaged in a pump-and-dump scheme involving the retailer's stock.

-Bill Peters

	

(END) Dow Jones Newswires

September 28, 2022 08:15 ET (12:15 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.